Research
Hormonal
Higher circulating estrogen levels in women are predictive of increased rates of nausea and vomiting when taking GLP-1 receptor agonists, and estrous cycle phase modulates drug sensitivity in female mice.
Your risk of side effects from GLP-1 drugs may fluctuate with your menstrual cycle, peaking when estrogen is highest. While this paper used mice, human data suggests higher estrogen levels correlate with more nausea. Tracking your cycle might help you and your doctor anticipate and manage side effects.
GoodConditionalHIGH confidence
We found that higher serum estradiol levels were clearly predictive of increased rates of nausea and vomiting in this cohort... estrous phase explained 17.8% of the variance in semaglutide-induced weight loss... being greatest during proestrus (when estrogen levels peak).
Why this rating
Strong preclinical data and consistent human EMR correlation, though human menstrual cycle tracking was not directly performed.
Source
Sex differences in GLP-1 signaling across species
Thomas Roseberry et al. · bioRxiv (Cold Spring Harbor Laboratory) · 2025
DOI 10.1101/2025.03.17.643822
preprint · n=2337Cited 5×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Females exhibit higher GLP-1 receptor (GLP1R) expression in specific brain regions (PBN, AP/NTS) involved in processing aversive stimuli, which may explain their heightened sensitivity to GLP-1 agonist-induced nausea.Strong
- Women experience a significantly lower efficacy-to-tolerability ratio than men when treated with GLP-1 receptor agonists, characterized by disproportionately higher rates of persistent nausea and vomiting relative to weight loss.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →